$1.88
−0.53%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.86
From 52W high−63.35%
Volume90430.00
Market cap$39.55M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.86
From 52W high
−63.35%
Volume
90430.00
Market cap
$39.55M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
32.0
MomentumView details →
1D Return
−0.53%
YTD Return
−46.97%
SummaryUpdated Jun 1, 2026
Grace Therapeutics, Inc. (NASDAQ:GRCE) is a clinical-stage biotechnology company focused on developing pharmaceutical treatments for rare and orphan diseases. Originally incorporated in 2002 as Acasti Pharma Inc., the company underwent a strategic transformation and rebranded to Grace Therapeutics in October 2024. Headquartered in Princeton, New Jersey, the company went public in February 2012 and has since pivoted from its original focus to concentrate on addressing unmet medical needs in rare disease populations where treatment options are limited or non-existent.
Similar companies
Latest newsMore news →
Grace Therapeutics announced its financial results for the first quarter of fiscal 2027 (three months ended June 30, 2026).68d agoGrace Therapeutics announced a $10 million private placement, with expected gross proceeds anticipated to extend the company's cash runway to the end of calendar 2028.76d agoGrace Therapeutics received Type A meeting minutes from the U.S. Food and Drug Administration regarding a Complete Response Letter for GTx-104.84d ago